(Q35591086)

9 August 2017

1 reference

title

New insights into the pathophysiology and management of bone disease in multiple myeloma (English)

1 reference

9 August 2017

1 reference

1 reference

Evangelos Terpos

1

1 reference

9 August 2017

Marianna Politou

series ordinal

2

1 reference

9 August 2017

Amin Rahemtulla

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

British Journal of Haematology

9 August 2017

published in

1 reference

9 August 2017

volume

123

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

758-769

1 reference

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Multiple myeloma: evolving genetic events and host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Bisphosphonates: a review of their pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Oral bisphosphonates: A review of clinical use in patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Multiple myeloma biology: lessons from the 5TMM models

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Anti-myeloma activity of pamidronate in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Immunocytochemistry reveals RANKL expression of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Bisphosphonates in early multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04712.X

10.1046/J.1365-2141.2003.04712.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference